Surgery for lymph node metastases of medullary thyroid carcinoma: A review

被引:42
作者
Jin, Linda X. [1 ]
Moley, Jeffrey F. [2 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Surg, Sect Endocrine & Oncol Surg,Siteman Canc Ctr, St Louis, MO 63110 USA
[3] St Louis Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA
关键词
endocrine disease; lymph node metastases; medullary thyroid carcinoma; pediatric oncology; surgery; ENDOCRINE NEOPLASIA TYPE-2; RET PROTOONCOGENE; PROPHYLACTIC THYROIDECTOMY; CLINICAL-CHARACTERISTICS; MALIGNANT PROGRESSION; PROGNOSTIC-FACTORS; DISEASE PHENOTYPE; MEN; 2A; CALCITONIN; MUTATIONS;
D O I
10.1002/cncr.29761
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the thyroid C cells that occurs in hereditary and sporadic clinical settings. Metastatic spread commonly occurs to cervical and mediastinal lymph nodes. MTC cells do not concentrate radioactive iodine and are not sensitive to hormonal manipulation, and therefore surgery is the most effective option for curative therapy, reduction in tumor burden, or effective palliation. In patients undergoing preventative surgery for hereditary MTC, central lymph node dissection should be considered if the calcitonin level is elevated. Preservation of parathyroid function in these young patients is of paramount importance. In patients with established primary tumors, systematic surgical removal of lymph node basins (compartmental dissection) should be guided by ultrasound mapping of lymph node metastases and level of serum calcitonin. A berry-picking approach is discouraged. Newly approved targeted molecular therapies offer wider treatment options for patients with progressive or metastatic disease. Cancer 2016;122:358-366. (c) 2015 American Cancer Society.
引用
收藏
页码:358 / 366
页数:9
相关论文
共 53 条
[1]  
BERGHOLM U, 1990, ACTA CHIR SCAND, V156, P37
[2]  
BLOCK MA, 1978, ARCH SURG-CHICAGO, V113, P368
[3]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[4]  
Bulkley GB, 1999, ANN SURG, V229, P887
[5]  
Cady B, 1997, SURGERY, V122, P1130
[6]   Gastrointestinal manifestations of multiple endocrine neoplasia type 2 [J].
Cohen, MS ;
Phay, JE ;
Albinson, C ;
DeBenedetti, MK ;
Skinner, MA ;
Lairmore, TC ;
Doherty, GM ;
Balfe, DM ;
Wells, SA ;
Moley, JF .
ANNALS OF SURGERY, 2002, 235 (05) :648-654
[7]   Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: Is parathyroid transplantation indicated? [J].
Decker, RA ;
Geiger, JD ;
Cox, CE ;
Mackovjak, M ;
Sarkar, M ;
Peacock, ML .
WORLD JOURNAL OF SURGERY, 1996, 20 (07) :814-821
[8]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[9]  
Dottorini ME, 1996, CANCER, V77, P1556, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO
[10]  
2-Y